LCM
CORT icon

Legato Capital Management’s Corcept Therapeutics CORT Stock Holding History

Legato Capital Management’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.58M Buy
41,186
+32,470
+373% +$1.96M 0.3% 92
2026
Q1 		$351K Buy
+8,716
New +$326K 0.03% 605
2025
Q4 		– Sell
-17,982
Closed -$1.49M – 767
2025
Q3 		$1.49M Buy
17,982
+4,110
+30% +$297K 0.16% 187
2025
Q2 		$1.02M Sell
13,872
-14,103
-50% -$1.02M 0.12% 269
2025
Q1 		$3.2M Sell
27,975
-4,341
-13% -$264K 0.43% 44
2024
Q4 		$1.63M Sell
32,316
-1,725
-5% -$90.4K 0.21% 146
2024
Q3 		$1.58M Buy
34,041
+9,985
+42% +$355K 0.19% 167
2024
Q2 		$782K Buy
24,056
+8,680
+56% +$238K 0.11% 323
2024
Q1 		$387K Hold
15,376
– – 0.05% 478
2023
Q4 		$499K Hold
15,376
– – 0.07% 416
2023
Q3 		$419K Sell
15,376
-6,125
-28% -$177K 0.06% 434
2023
Q2 		$478K Hold
21,501
– – 0.06% 427
2023
Q1 		$466K Hold
21,501
– – 0.08% 369
2022
Q4 		$437K Buy
+21,501
New +$539K 0.08% 372

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Legato Capital Management's CORT Position: Q2 2026 in Review

Legato Capital Management increased its Corcept Therapeutics (CORT) stake by 373% in Q2 2026, buying an estimated $1.96M and bringing the position to 41,186 shares worth $3.58M. The position accounts for 0.3% of the portfolio, ranked #92.

Legato Capital Management first reported a position in CORT in Q4 2022 and has held it in 14 quarters since. 422 funds tracked by Wall St. Rank hold CORT as of Q2 2026.

  • Legato Capital Management held 41,186 shares of Corcept Therapeutics worth $3.58M as of Q2 2026.
  • Legato Capital Management bought 32,470 Corcept Therapeutics shares in Q2 2026, an estimated $1.96M.
  • Corcept Therapeutics made up 0.3% of Legato Capital Management's portfolio in Q2 2026, its #92 holding.
  • Legato Capital Management first reported a position in Corcept Therapeutics in Q4 2022 and has held it in 14 quarters since.
  • 422 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q2 2026.

Based on Legato Capital Management's 13F filing for Q2 2026, filed 6 Aug 2026.